Member Info for jackdaw99

Traders selling out for 10%. Let them.

"... and not just chaff lifted from the web (not suggesting this is the latter)." Well, it wasn't. IMO it was a well-reasoned immunological and financial analysis, and almost certainly more neutral than you might get from almost any company or nominated broker which would, of course, be somewhat biased! Anyway let's leave it there - if folk want to read it they can.

"What is contained within the Interims in just a couple of weeks time, will overtake this ie. horses mouth." I suppose it's always true that the latest news surpasses everything else but, nevertheless, Sci102's report makes some interesting points -and far more insightful than 90% of the material on SCLP boards.

... of last week's frenzy? Someone much bigger wants this and it leaked. Everyone in on the leak rushed in to get their share until they were satisfied, knowing approximately what the outcome would be. No further insiders in the know so buying stopped and now they wait. I'm hoping not for long. Fanciful, yes, but we've seen everything over the last few years...

Picathartes .... never seen it, but I would love to!

RNS Number : 1234L

ReNeuron Group plc

04 September 2023

ReNeuron Group plc

("ReNeuron", the "Company" or the " Group")

R&D Update

Creating a valuable and differentiated Exosome Delivery Platform

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.

Randolph Corteling, Chief Scientific Officer, commented: "I am pleased to confirm that over the last six months we have generated comparative in vivo data demonstrating distinct organ and cellular targeting capabilities of our proprietary stem-cell derived exosomes, which differentiates our CustomEX(TM) platform from that of our competitors."

Iain Ross, Executive Chairman, said: "On the basis of this data the Company will now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads. We look forward to updating shareholders in due course."

Might be interesting?

Sort of agree, but Good Friday Agreement??

Blair will 'represent' anybody for enough cash. There's an idea.

JB1, yes I'd seen it but thanks for the reminder. Some interesting trades today and yesterday. Off to the races??

"Jackdaw, if the current vaccines had a strong memory effect, we wouldn't need an annual booster." First, the immune memory is how vaccinations work at all, so existing vaccines obviously stimulate memory T-cells. How strong? Well, the issue with renewed annual shots is not necessarily the loss of immune memory, although it could be, but more usually the incessant mutation of the virus. If the mutation is sufficiently diverse then the memory of the previous version is only of so much use. Obviously, we hope that Scancell's vaccines will be less conservative in their targetting of antigen!

"What is clear is that the current vaccines do not have a strong memory effect." Could be, but I haven't seen clear evidence.

"Couple that with the fact that Covidity targets N Protein epitopes which is a protein well preserved in variants, it also promises to be effective against new variants coming along." Could well prove to be true. Let's hope so.

Evidence?

Obviously, but my comment was in response to this claim "It is very clear now that the current batch of jabs don't offer long term protection ". I'm saying "It's not clear". That should be clear.

Critical point is you don't know how severe the illness would have been without the vaccinations.

I seem to have been given about 70% more then my "allocation". Anyone else?

They may well be but RENE have moved a bit away from stem cells in the last two years. Perhaps something else is also the future?

... all round for bios though, so who knows?

... or more data from trials.

We'll probably see Novo buying again. Good climate for them.